Pular para o conteúdo
Radio Logo
PodcastsCiênciaPharma and BioTech Daily

Pharma and BioTech Daily

Pharma and BioTech News
Último episódio

48 episódios

  • Pharma and BioTech Daily

    Pfizer bets on in vivo CAR T, Merck drops nemtabrutinib | Pharma and Biotech Daily

    19/11/2026 | 5min
    Pfizer licenses three in vivo CAR T programs from China's Starna Therapeutics in a deal worth up to 2.6 billion dollars, and Merck ends its nemtabrutinib program after a Phase 3 benefit risk review. Also: the FDA's published rejection letter for Summit's ivonescimab, Bristol Myers Squibb's Cobenfy data in Alzheimer's psychosis, and Biogen's protein degrader pact with Trimtech.

    Good morning from Pharma and Biotech Daily, the briefing on what matters in pharma and biotech. It's Thursday, November 19.

    Today, Pfizer makes its first move into in vivo CAR T with a Chinese partner, and Merck shuts down an entire blood cancer program after a Phase three safety review.

    First, Pfizer. According to BioSpace, the company has licensed three autoimmune CAR T programs from Starna Therapeutics, a Chinese company that builds RNA medicines delivered through targeted lipid nanoparticles. Pfizer pays three hundred thirty million dollars upfront, with up to two point three billion more in milestones plus royalties, for a total of up to two point six billion. All three programs are preclinical, and Pfizer also gains rights to use the platform in immunology and in oncology. This is the company's first in vivo cell therapy work, after earlier ex vivo efforts in cancer. Why it matters: making CAR T cells inside the body could remove the cell harvesting and manufacturing that keep these therapies out of most autoimmune clinics, and big pharma keeps sourcing that innovation from China.

    Next, Merck. The company said on Tuesday afternoon it is ending development of nemtabrutinib, its oral non covalent BTK inhibitor, across the whole BELLWAVE program. An external data monitoring committee reviewed the Phase three BELLWAVE eleven study in chronic lymphocytic leukemia and signaled that the benefits may not outweigh the risks. Merck's own review of the data agreed, so the BELLWAVE eight and BELLWAVE ten Phase three trials stop as well. Fierce Biotech framed it as the end of a two point seven billion dollar program. For the market, the decision removes a would be challenger to the established BTK drugs in leukemia, and it is a reminder that a late stage asset can fall away on a single interim look.

    An update on the story we covered on Monday. The FDA has published the rejection letter for Summit Therapeutics and Akeso's ivonescimab in EGFR mutated lung cancer, and it goes beyond the overall survival miss. Fierce Pharma reports that ninety three percent of progression free survival events came from patients enrolled in China, and the agency said it could not tell whether the results apply to American patients. Median progression free survival rose from four point four to six point eight months, a gain the FDA called modest against added toxicity. It wants a new global trial. BioPharma Dive quotes a Leerink analyst saying a fresh application alone is unlikely to change the outcome. The lesson for sponsors: trials built mostly in one country face hard questions in Washington.

    Turning to Alzheimer's. At the CTAD meeting in Boston on Wednesday, Bristol Myers Squibb presented data on Cobenfy, xanomeline and trospium, in psychosis linked to Alzheimer's disease. BioSpace reports that in ADEPT one, two hundred seventy three patients who completed a twelve week open label phase showed fewer hallucinations and delusions, though the relapse results and placebo comparisons were held back. Treatment related adverse events reached about fifty seven percent in that study and sixty five percent in the year long ADEPT three extension, which caught analysts' attention. Bristol has also moved to three times daily dosing. The randomized ADEPT two readout is now expected in twenty twenty seven, so the commercial case in this population stays open for another year.

    Finally, a neuroscience deal. BioPharma Dive reports that Biogen is paying Trimtech Therapeutics more than thirty two million dollars upfront to develop small molecule protein degraders for neurodegenerative disease. The molecules are designed to cross into the central nervous system and clear toxic protein buildups. Biogen holds an option to license the resulting drugs exclusively and would then fund development and sales, while Trimtech could earn up to four hundred eleven million dollars in milestones plus royalties. The structure keeps Biogen's upfront exposure small while it buys access to a modality that has mostly been tested in cancer, and it shows the company rebuilding its brain pipeline through partnerships.

    The common thread today is risk being priced in public: in early platforms bought with options, in late stage programs cut on safety, and in regulators asking where the data came from.

    That's the briefing for today. Pharma and Biotech Daily is produced by OWITH.ai. See you tomorrow.

    Sources:
    https://www.biospace.com/business/pfizer-launches-into-autoimmune-car-t-with-chinas-starna-in-up-to-2-6b-deal
    https://fiercebiotech.com/biotech/pfizer-enters-vivo-car-t-space-3-program-26b-deal-chinas-starna
    https://www.merck.com/news/merck-announces-update-on-bellwave-clinical-development-program-evaluating-nemtabrutinib/
    https://fiercebiotech.com/biotech/merck-axes-27b-btk-inhibitor-program-after-seeing-phase-3-data
    https://download.open.fda.gov/crl/CRL_BLA761524_20261113.pdf
    https://www.fiercepharma.com/pharma/fdas-complete-response-letter-summit-ivonescimab-cites-china-heavy-data-beyond-survival-miss
    https://www.biopharmadive.com/news/summit-crl-sellas-data-nelkarmi-lilly-astrazeneca-biogen/874825/
    https://www.biospace.com/drug-development/CTAD-2026-bms-cobenfy-eases-alzheimer's-psychosis-as-expected-but-safety-events-raise-questions

    Pharma and Biotech Daily is produced by OWITH.ai. Script and voice are AI generated from the public sources listed above. Not medical or investment advice.Support the show
  • Pharma and BioTech Daily

    FDA nods GSK's Nelkarmi, Isomorphic raises record 5B dollars | Pharma and Biotech Daily

    18/11/2026 | 4min
    GSK wins accelerated FDA approval for Nelkarmi in previously treated ALK positive lung cancer, and Isomorphic Labs raises a record 5 billion dollar Series C. Also: Lilly's oncology pact with Stipple Bio worth up to 5.9 billion dollars and a split Phase 3 result for AriBio's AR1001 in Alzheimer's disease.

    Good morning from Pharma and Biotech Daily, the briefing on what matters in pharma and biotech. It's Wednesday, November 18.

    Today, GSK wins an early FDA nod for its new lung cancer drug, and Isomorphic Labs sets a record for a private biotech raise.

    We start with the regulator. GSK says the FDA has granted accelerated approval to Nelkarmi, known generically as neladalkib, for adults with advanced ALK positive non small cell lung cancer whose disease has already been treated. The decision came ahead of the November twenty seventh target date. It rests on the ALKOVE one study of two hundred twenty two patients. In those who had only received alectinib before, forty nine percent responded, and in more heavily treated patients the figure was thirty two percent. Liver toxicity was the most common side effect. The drug came to GSK through its purchase of Nuvalent, so this is an early return on that bet. A Phase three trial called ALKAZAR is testing it in patients who have not yet had an ALK drug.

    Now to money. BioSpace reports that Isomorphic Labs, the London based artificial intelligence drug designer owned by Alphabet, has raised a five billion dollar Series C. Greenoaks and Sequoia Capital led the round, with Alphabet investing again. That is the largest private raise the sector has seen, more than double the two point one billion dollars Isomorphic collected in May, and it brings its total to at least seven point seven billion. The striking part is that the company has not yet named a clinical candidate. It points to preclinical work in oncology and immunology and to partnerships with Novartis, Eli Lilly and Johnson and Johnson. Investors are paying up front for a platform, and the clinic will now have to justify that price.

    Lilly, meanwhile, keeps building its cancer pipeline. BioSpace reports that it signed a multi target oncology licensing deal with Stipple Bio, announced alongside its Calytrix Bio buyout, which we covered yesterday. Stipple's Pointillist platform looks for binders to surface markers found only on tumor cells, with the goal of hitting cancer while sparing healthy tissue. Lilly takes worldwide rights and makes an equity investment, plus an undisclosed upfront payment. Stipple could earn up to five point nine billion dollars in development and sales milestones. The young company raised a one hundred million dollar Series A in June to move its first antibody drug conjugate, STP one hundred, toward early trials, and it already has a conjugate collaboration with Lonza. The pattern is clear: Lilly is turning its obesity revenue into a steady stream of early stage bets.

    Finally, a mixed result in Alzheimer's disease. AriBio presented topline data from its Phase three POLARIS AD trial of AR1001, a once daily oral pill that works as a brain penetrant PDE5 inhibitor. In all one thousand five hundred thirty five patients, the drug did not separate from placebo on the CDR sum of boxes score at one year. The trial's design allowed success in either of two prespecified groups, and in six hundred four patients not taking other Alzheimer's drugs, decline slowed by thirty one percent. Diarrhea and dizziness were more common on the drug, and more patients stopped because of side effects. AriBio will take the full data to the FDA before deciding next steps. Regulators tend to look hard at subgroup wins, so expect a careful conversation.

    The thread today is conviction under uncertainty: a single arm approval, a platform without a drug in the clinic, a milestone heavy licensing deal and a subgroup result, each asking someone to bet before the full picture is in.

    That's the briefing for today. Pharma and Biotech Daily is produced by OWITH.ai. See you tomorrow.

    Sources:
    https://www.biospace.com/press-releases/nelkarmi-neladalkib-approved-in-the-us-for-previously-treated-advanced-alk-positive-non-small-cell-lung-cancer
    https://www.biospace.com/drug-development/isomorphic-labs-breaks-biotech-vc-fundraising-record-with-5b-series-c
    https://www.biospace.com/business/lilly-pens-another-deal-inking-up-to-5-9b-oncology-pact-with-stipple
    https://www.globenewswire.com/news-release/2026/11/17/3404242/0/en/aribio-s-oral-ar1001-meets-primary-efficacy-objective-in-prespecified-monotherapy-population-in-phase-3-polaris-ad-trial.html

    Pharma and Biotech Daily is produced by OWITH.ai. Script and voice are AI generated from the public sources listed above. Not medical or investment advice.Support the show
  • Pharma and BioTech Daily

    J&J buys Ollin for $2.2B, FDA approves Roche's giredestrant | Pharma and Biotech Daily

    17/11/2026 | 6min
    Johnson & Johnson pays $2.2 billion upfront for Ollin Biosciences and its Vabysmo challenger OLN324, and the FDA approves Genentech's Wilserdly (giredestrant) for ESR1 mutated breast cancer. Also: Helus Pharma's Phase 3 depression win, Lilly's purchase of Calytrix Bio, Seawolf's Sanofi pact and Novartis' ADC deal with OBI Pharma.

    Good morning from Pharma and Biotech Daily, the briefing on what matters in pharma and biotech. It's Tuesday, November 17.

    Today, Johnson and Johnson pays two point two billion dollars upfront for an eye drug built to take on Roche, and the FDA clears Genentech's oral breast cancer pill giredestrant.

    We start with the biggest deal of the day. Johnson and Johnson is acquiring Ollin Biosciences, according to BioPharm International and Fierce Biotech. The upfront price is two point two billion dollars, with up to about one point one billion more in regulatory and commercial milestones. The prize is OLN324, a compact bispecific antibody that blocks both VEGF and Ang2, licensed from Innovent, for wet age related macular degeneration and diabetic macular edema. That is the same dual mechanism behind Roche's Vabysmo, faricimab. In a Phase one b study called JADE, eighty two percent of patients on OLN324 went twelve weeks without retreatment, against eighty one percent on faricimab. Blackstone Life Sciences will put seven hundred fifty million dollars toward the Phase three program in return for milestones and royalties. Closing is expected before year end. For retina specialists, the real contest will be dosing intervals.

    Next, a regulatory win in breast cancer. The FDA has approved Wilserdly, giredestrant, from Roche's Genentech unit, in combination with everolimus, as reported by CancerNetwork. It covers ER positive, HER2 negative advanced breast cancer with an ESR1 mutation after prior endocrine therapy, with the FoundationOne Liquid CDx blood test used to find eligible patients. In the Phase three evERA trial, median progression free survival in the ESR1 mutated group reached ten months, compared with five and a half months on standard endocrine therapy plus everolimus. Overall survival data are still immature. Giredestrant is an oral estrogen receptor degrader, and this approval gives Roche an oral option for patients whose tumors carry the ESR1 mutation.

    In psychiatry, Helus Pharma reported a Phase three win for HLP003, a modified form of psilocin, as an add on treatment for major depression. In the APPROACH study of two hundred twenty two adults, depression scores at week six fell seven point six points more on HLP003 than on placebo, and the gap was already visible on day two. Remission at week six reached about fifty one percent, against eighteen percent on placebo. The company reported three serious adverse events judged related to treatment and no new safety signals. A second pivotal study, EMBRACE, reads out in the fourth quarter of twenty twenty seven. With Compass Pathways already filed, psychedelic medicine is moving from niche to late stage pipeline.

    Eli Lilly is buying again. BioPharma Dive reports Lilly will pay up to one point five billion dollars for Calytrix Bio, a young Massachusetts company working on myelofibrosis and essential thrombocythemia. Calytrix has a biparatopic antibody, meaning it grips two sites on the same protein, aimed at a surface marker found in disease driven by CALR mutations. Calytrix argues that current options, such as Incyte's Jakafi, mostly manage symptoms. This is Lilly's fifteenth announced company acquisition this year, with more than thirty billion dollars spent, most of it on private startups. No other drugmaker has been as active in deals this year.

    Two platform deals round out the day. Seawolf Therapeutics came out of stealth with one hundred million dollars in seed and Series A money and a Sanofi pact worth up to one point two billion dollars in milestones, according to Fierce Biotech and BioPharm International. Its TRIDENT platform packs DNA, rather than RNA, into lipid nanoparticles, with the aim of longer protein expression and repeat dosing that viral gene therapy struggles to offer. Sanofi's first targets are bleeding disorders. Investors include Versant Ventures, the Novartis Venture Fund, Lilly and CRISPR Therapeutics.

    Meanwhile, Novartis signed a licensing deal with Taiwan's OBI Pharma for its glycan based conjugation technology, which links drug payloads to antibodies through their sugar chains, including a version that carries two payloads at once. Novartis pays thirty million dollars upfront, with a total potential value above two billion dollars plus royalties. The bet is that the next gains in antibody drug conjugates will come from new payloads and smarter attachment chemistry.

    The thread running through today is that big pharma is buying the next generation of proven ideas, from a better shot for the eye to new ways of delivering genes and payloads, and in the case of Johnson and Johnson, sharing the cost with a financial partner.

    That's the briefing for today. Pharma and Biotech Daily is produced by OWITH.ai. See you tomorrow.

    Sources:
    https://www.biopharminternational.com/view/deals-roundup-j-j-buys-ollin-lilly-adds-calytrix-and-novartis-and-sanofi-strike-platform-pacts
    https://www.fiercebiotech.com/biotech/jj-pays-22b-upfront-ollin-challenge-roches-vabysmo
    https://www.cancernetwork.com/view/fda-approves-giredestrant-everolimus-for-er-her2-esr1-mutated-breast-cancer
    https://www.manilatimes.net/2026/11/16/tmt-newswire/globenewswire/helus-pharma-announces-positive-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder/2470802
    https://www.biopharmadive.com/news/lilly-calytrix-bio-acquire-deal-myelofibrosis-essential-thrombocythemiaenial-/874719/
    https://fiercebiotech.com/biotech/lilly-secures-another-myelofibrosis-option-15b-deal-jpm-founded-calytrix
    https://www.fiercebiotech.com/biotech/dna-delivery-biotech-seawolf-surfaces-alongside-investors-novartis-lilly-and-partner-sanofi
    https://biospace.com/press-releases/obi-pharma-signs-collaboration-and-license-agreement-with-novartis

    Pharma and Biotech Daily is produced by OWITH.ai. Script and voice are AI generated from the public sources listed above. Not medical or investment advice.Support the show
  • Pharma and BioTech Daily

    FDA rejects Summit's ivonescimab, EU backs AstraZeneca Baxfendy | Pharma and Biotech Daily

    16/11/2026 | 5min
    The FDA has rejected Summit and Akeso's lung cancer antibody ivonescimab over a missing overall survival win, while Europe's CHMP backed AstraZeneca's blood pressure drug Baxfendy and two China origin lung cancer medicines. We also cover Zevra's upheld refusal in Europe and Cellectis' deep job cuts as it pivots to in vivo gene editing.

    Good morning from Pharma and Biotech Daily, the briefing on what matters in pharma and biotech. It's Monday, November 16.

    Since Friday, the FDA has turned down Summit Therapeutics' lung cancer antibody ivonescimab, and Europe's drug committee has backed AstraZeneca's blood pressure pill Baxfendy along with two lung cancer drugs that came out of China.

    An update on the story we covered last Monday. Summit said on Sunday that the FDA issued a complete response letter for ivonescimab, its P D one and V E G F bispecific antibody partnered with Akeso, filed with chemotherapy for E G F R mutated lung cancer. According to the company release, carried by BioSpace, the agency said a progression free survival benefit without a statistically significant overall survival gain did not establish effectiveness. Summit points to a later analysis with a hazard ratio of zero point seven six, but that came after the primary test. Summit gave no resubmission plan. The verdict keeps the whole P D one and V E G F class off the US market for now, and sets a high bar for overall survival.

    Over in Amsterdam, the European Medicines Agency's human medicines committee, the C H M P, published the results of its November meeting on Friday. The headline new medicine is Baxfendy, the brand name for baxdrostat from AstraZeneca, recommended for adults with hypertension. Baxdrostat blocks aldosterone synthase, the enzyme that makes aldosterone, a hormone that raises blood pressure. A positive opinion goes to the European Commission, which usually issues a final decision within about two months. For AstraZeneca, it is an important European step for a newer kind of blood pressure medicine, one aimed at a very large group of patients.

    The same committee meeting also cleared a path for two lung cancer medicines with roots in China. Aumseqa, or aumolertinib, an E G F R inhibitor that Fierce Pharma links to Hansoh, won a positive opinion for non small cell lung cancer. Fierce describes the result as a second chance for the drug in Europe. The committee also backed Zybrivo, or sintilimab, a P D one antibody filed by Fortvita Biologics, for non squamous non small cell lung cancer. Together they show Chinese developed oncology drugs moving into Western markets through Europe, even as US regulators remain demanding about trial data.

    Not every company left the meeting happy. On re-examination, the committee confirmed its refusal of Meplyffa, arimoclomol from Zevra, for Niemann Pick disease type C, so the drug will not reach European patients on this application. Alexion, part of AstraZeneca, withdrew its application for anselamimab in kappa light chain amyloidosis. On the positive side, Roche's Gazyvaro, obinutuzumab, gained a recommendation for adults with moderate to severe active lupus. The agency also flagged a safety letter for Mounjaro, advising women on oral contraceptives to add a barrier method for four weeks after starting the drug and after each dose increase.

    Finally, a gene editing reset. BioSpace reports that French biotech Cellectis may cut up to seventy percent of its global staff, about one hundred sixty people. The cuts follow a September decision to leave allogeneic CAR T behind and focus on in vivo gene editing for chronic disease. The lead candidates are HEAL one oh one, a base editor aimed at A P O C three for severe hypertriglyceridemia, and HEAL two oh one, an epigenetic editor targeting P C S K nine. Both will start in investigator led trials in China, with first data due in the second half of twenty twenty seven. Cellectis had one hundred forty nine million dollars at the end of September, which it expects to last into the second half of twenty twenty eight.

    The thread today is evidence. Regulators on both sides of the Atlantic are asking hard questions about what a drug truly delivers, and companies are reshaping their pipelines to give clear answers.

    That's the briefing for today. Pharma and Biotech Daily is produced by OWITH.ai. See you tomorrow.

    Sources:
    https://www.biospace.com/press-releases/summit-therapeutics-provides-update-regarding-ivonescimab-biologics-license-application
    https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-november-2026
    https://www.fiercepharma.com/pharma/europes-chmp-signed-stack-new-medicines-including-azs-bp-med-and-2-entrants-china
    https://www.biospace.com/job-trends/cellectis-could-cut-70-of-workforce-in-shift-to-in-vivo-therapies

    Pharma and Biotech Daily is produced by OWITH.ai. Script and voice are AI generated from the public sources listed above. Not medical or investment advice.Support the show
  • Pharma and BioTech Daily

    Pfizer Blackstone 1.5B obesity deal, FDA vouchers shelved | Pharma and Biotech Daily

    13/11/2026 | 5min
    Blackstone commits up to 1.5 billion dollars to Pfizer's monthly obesity shot berobenatide, and Reuters reports the FDA has shelved its Commissioner's National Priority Voucher program. Also: FDA staffing gaps, a Bristol Myers Squibb R&D overhaul, Windward Bio's 175 million dollar IPO and a 105 million dollar Series B for Neurosterix.

    Good morning from Pharma and Biotech Daily, the briefing on what matters in pharma and biotech. It's Friday, November 13.

    Today, private equity puts up serious money behind a Pfizer obesity drug, and a report says the FDA has quietly parked its fast track voucher program.

    We start with Pfizer. Blackstone Life Sciences will provide up to one point five billion dollars to help fund berobenatide, a potential once a month G L P one injection that Pfizer gained through its roughly ten billion dollar purchase of Metsera. BioPharma Dive reports the money arrives in phases through 2028 and supports as many as ten Phase three trials. Pfizer pays Blackstone milestones only if the FDA approves the drug as a monthly single agent for weight management and sales targets are met. The deal matters because it shifts part of the cost of a very large obesity program off Pfizer's books, just as generic competition for Eliquis and Ibrance starts to weigh on earnings.

    Next, Washington. BioSpace, citing Reuters, reports that the FDA has effectively shelved the Commissioner's National Priority Voucher program launched by former commissioner Marty Makary. Companies can still apply, but according to six people quoted by Reuters, those applications are not moving forward. Twenty two drugs received a voucher and twelve have been approved, yet none have been awarded since Makary left in May. An FDA spokesperson says the pilot is ongoing and career staff continue to review applications. Holders such as Compass Pathways now face more timeline uncertainty, while the Senate committee vote on commissioner nominee Heidi Overton is set for November 18.

    Staying with the agency, a separate BioPharma Dive analysis finds the FDA's drug and biologics centers had one thousand three hundred forty three fewer employees in September than two years earlier. Hiring is slow, and companies report that informal feedback from reviewers is harder to get. That can mean extra meetings and pre submissions, adding time and cost. Lawyers who advise drugmakers expect rebuilding the workforce to take a year or two. The practical message for development teams is to plan regulatory timelines with more slack, especially at smaller companies with less cash to absorb delays.

    At Bristol Myers Squibb, research chief Robert Plenge is leaving, and the company is combining research and development into a single organization. Chief medical officer Cristian Massacesi becomes head of R and D on January first, while Plenge stays through March to help with the handover. BioPharma Dive notes the company says the change will speed decisions and sharpen portfolio management. It comes as Eliquis, which brought in more than fourteen billion dollars last year, heads toward patent expiry, and after recent setbacks including a failed Camzyos study.

    In capital markets, Swiss immune drug developer Windward Bio priced a one hundred seventy five million dollar IPO, selling shares at seventeen dollars, with trading set to begin today under the ticker W W B. Sanofi is buying another fifty million dollars in a private placement. Windward's lead drug, WIN three seventy eight, targets the same protein as Tezspire but could be given as rarely as twice a year. Both of its programs were licensed from Chinese companies. BioPharma Dive counts this as the sector's thirtieth IPO of the year, which makes 2026 the busiest year for drugmaker listings since 2021.

    Finally, private funding. BioSpace reports that Neurosterix, a spinout of Swiss biotech Addex Therapeutics, raised a one hundred five million dollar Series B led by RTW Investments, with GV and Janus Henderson also taking part. The money will move NTX two fifty three, an oral drug that modulates the M four muscarinic receptor, into Phase two testing in schizophrenia. The company has added several Karuna veterans to its board and clinical advisory ranks. The round is up sharply from its sixty three million dollar Series A in 2024, a sign that investors still want exposure to the muscarinic approach to psychosis, which aims to avoid the movement and metabolic side effects of older antipsychotics.

    The thread running through today is capital and capacity: money is finding its way to late stage and well understood bets, while the regulator that ultimately judges them is running thinner and less predictable.

    That's the briefing for today. Pharma and Biotech Daily is produced by OWITH.ai. See you on Monday.

    Sources:
    https://www.biopharmadive.com/news/blackstone-pfizer-berobenatide-deal/874483/
    https://www.biospace.com/business/pfizer-snags-1-5b-financing-from-pe-firm-blackstone-to-support-metsera-asset
    https://www.biospace.com/fda/fdas-commissioner-voucher-program-reportedly-shuttered-ahead-of-senate-vote-on-overton
    https://www.biopharmadive.com/news/fda-staffing-shortages-drug-reviews-pharma/874480/
    https://www.biopharmadive.com/news/bristol-myers-robert-plenge-cristian-massacesi-research-transition/874476/
    https://www.biospace.com/business/bms-r-d-head-to-depart-amid-restructure
    https://www.biopharmadive.com/news/windward-ipo-pricing-immune-drugs-china-deals-tezspire/874533/
    https://www.biospace.com/drug-development/neurosterix-nabs-105m-recruits-karuna-veterans-for-schizophrenia-push

    Pharma and Biotech Daily is produced by OWITH.ai. Script and voice are AI generated from the public sources listed above. Not medical or investment advice.Support the show
Mais podcasts de Ciência
Sobre Pharma and BioTech Daily
Pharma & Biotech Daily is a short, AI-generated, human-supervised briefing on what’s important in pharma and biotech.Each weekday we condense key news on pipelines, deals, regulation and strategy into a quick audio update for people who build, run and invest in life sciences.Produced by OWITH.ai, a boutique AI & data studio. Sponsor the show: https://sponsor.owith.ai
Site de podcast

Ouça Pharma and BioTech Daily, StarTalk with Neil deGrasse Tyson e muitos outros podcasts de todo o mundo com o aplicativo o radio.net

Obtenha o aplicativo gratuito radio.net

  • Guardar rádios e podcasts favoritos
  • Transmissão via Wi-Fi ou Bluetooth
  • Carplay & Android Audo compatìvel
  • E ainda mais funções